A short 14 day phase 1 study examining 6 monotherapy doses of oral tamoxifen for safety in chronic HCV patients who have failed standard treatment of peginterferon and ribavirin.

Six different dosages of tamoxifen will be given for 14 days with safety and viral loads being measured.

Inclusion Criteria:

1. HCV RNA positive.
2. failed standard therapy

Exclusion Criteria:

1. Cirrhosis on biopsy
2. Severe medical or psychiatric conditions that would make the evaluation difficult
3. Tamoxifen is a pregnancy category D drug so pregnant women must be excluded.
4. Patients with coumadin cannot be used from a drug interaction.
5. Active use of alcohol or illegal substances -